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Abstract A tridecapeptide (MITLAIPVNKPGR) that stimu-
lates phagocytosis of human neutrophils was isolated from a
trypsin digest of soybean proteins. This peptide is derived
from the soybean L-conglycinin KP subunit and was named soy-
metide-13. The N-terminal methionine residue of soymetide-13
is essential for its activity, and removal of C-terminal residues
revealed that soymetide-4 (MITL) is the minimal structure re-
quired for phagocytosis stimulation. Although they are not for-
mylated at their N-termini, soymetides have a weak a⁄nity for
the N-formyl-methionyl-leucyl-phenylalanine (fMLP) receptor
and their phagocytosis-stimulating activity is inhibited by the
fMLP antagonist Boc-MLP. Interestingly, soymetide-4 pro-
motes tumor necrosis factor K production at a higher level
than soymetide-13 following oral administration in mice.
. 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Many immunostimulating peptides have been isolated from
enzymatic digests of various food proteins such as those
found in milk [1,2]. These peptides, which have speci¢c bind-
ing sites on human blood phagocytic cells, stimulate phago-
cytosis of human and murine macrophages in addition to
protecting mice from Klebsiella pneumoniae infection.
We isolated the immunostimulating peptide His-Cys-Gln-
Arg-Pro-Arg from a tryptic digest of soybean proteins [3].
This peptide, which has homology to tuftsin (Thr-Lys-Pro-
Arg) [4], is derived from a soybean glycinin subunit and can
activate phagocytosis of human neutrophils ; furthermore, it
stimulates tumor necrosis factor (TNF) production when it is
orally administered to mice. In this study, we searched for
other immunostimulating peptides that may be present in
tryptic soybean protein digests. We describe the isolation of
a peptide that acts as an agonist of the N-formyl-methionyl-
leucyl-phenylalanine (fMLP) receptor even though it is not
formylated at its N-terminus.
N-Formylmethionyl peptides are chemotactic for human
neutrophils and macrophages [5]. fMLP is a synthetic N-for-
mylmethionyl peptide that is strongly chemotactic for neutro-
phils [6], and a speci¢c fMLP receptor has been identi¢ed on
the surface of neutrophils and macrophages [7]. This receptor
also mediates the generation of reactive oxygen species (ROS)
from neutrophils and macrophages [8] as well as the phago-
cytosis-stimulating activity of neutrophils [9]. These functions
appear to contribute to a rapid response to bacterial infection
since bacterial proteins have an N-formylmethionine residue
at their N-termini. This response leads to bacterial death by
phagocytosis and ROS-induced bactericidal e¡ects.
We investigated the basic properties of this immunostimu-
lating peptide so that orally e¡ective immunostimulating
agents may eventually be developed.
2. Materials and methods
2.1. Reagents and chemicals
fMLP and Boc-MLP were purchased from Sigma Chemical Co. (St.
Louis, MO, USA). Soymetide-13 and its derivatives were synthesized
by a solid phase peptide synthesizer (PS3, Protein Technologies, Inc.,
Tucson, AZ, USA) according to the 9-£uoroenyl methoxycarbonyl
(Fmoc) method. Peptides were removed from the resin with tri£uoro-
acetic acid and puri¢ed with high performance liquid chromatography
(HPLC) and subsequent lyophilization.
2.2. Animals
Male ICR mice were purchased from Japan SLC, Inc. (Shizuoka,
Japan).
2.3. Enzymic digestion
5 g of the soybean protein isolate (SPI, Fuji Oil Co., Ltd., Osaka,
Japan) were resuspended in 80 ml water and centrifuged at 3000 rpm
for 20 min. The supernatant adjusted to pH 7.5 was boiled for 10 min.
Bovine pancreas trypsin was then added, and the solution was incu-
bated at 37‡C for 5 h. The reaction was stopped by boiling for 10 min,
and then the suspension was centrifuged at 10 000 rpm for 10 min.
The supernatant was used after lyophilization as soybean trypsin di-
gest.
2.4. Phagocytosis assay
Heparinized human venous blood was washed two times with phos-
phate-bu¡ered saline (PBS; 136.9 mM NaCl, 2.68 mM KCl, 1.47 mM
KH2PO4, and 8.04 mM Na2HPO4) containing glucose (GPBS; PBS
containing 5.55 mM glucose, 0.33 mM sodium pyruvate, 0.49 mM
MgCl2 and 0.90 mM CaCl2). 10 Wl of sample solution were added
to 100 Wl of prepared human blood cells in GPBS and the resulting
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mixture was incubated for 10 min at 37‡C. Next, 10 Wl of PBS-sus-
pended £uorescent beads opsonized with human serum were added to
the mixture, which was incubated for an additional 10 min at 37‡C.
The reaction was stopped by adding 3 ml of ice-cold PBS containing
4 mM ethylenediamine tetraacetic acid (EDTA) (EDTA-PBS). Erythro-
cytes were removed by lysing with NH4Cl solution (77.2 mM NH4Cl,
5 mM KHCO3, and 0.041 mM EDTA-4Na). Neutrophils were ana-
lyzed by EPICS PROFILE (Beckman Coulter, Inc., Fullerton, CA,
USA). The intensity of phagocytosis was shown as the phagocytic
index, which is presented as the number of incorporated £uorescent
beads per 100 neutrophils [10].
2.5. Puri¢cation of phagocytosis-stimulating peptides
100 mg of the soybean protein trypsin digest dissolved in 1 ml of
Tris^HCl bu¡er (pH 7.2) were applied to a DEAE-cellulose column
equilibrated with the same bu¡er, and the non-absorbed fraction was
obtained. This fraction was passed over an ODS column (Cosmosil
5C18-AR, 20U250 mm, Nacalai Tesque, Inc., Kyoto, Japan) and a
Phenetyl column (Develosil PhA-T-5, 4.6U250 mm, Nomura Chem-
ical Co., Ltd., Aichi, Japan) on a linear acetonitrile concentration
gradient (1%/min) in the presence of 0.1% tri£uoroacetic acid. The
fraction obtained in this step was then passed over an ODS column
on a linear acetonitrile concentration gradient (1%/min) in 10 mM
phosphate bu¡er (pH 7.4) to obtain the ¢nal sample. A protein se-
quencer (447A, Applied Biosystems, Inc., Foster City, CA, USA) was
used for structural determination of the obtained peptides.
2.6. fMLP receptor binding assay
Saline containing 3% (w/v) dextran (Nacalai Tesque, Inc., Kyoto,
Japan) was added to heparinized human peripheral blood. After 30
min, the supernatant fraction was collected, and contaminating eryth-
rocytes were hypotonically lysed. The neutrophil pellet was obtained
by centrifugation on Ficoll Paque (Amersham Pharmacia Biotech,
Inc., Piscataway, NJ, USA) at 500Ug for 20 min and was then sus-
pended in PBS (145 mM NaCl, 5 mM KCl, 1.9 mM NaH2PO2, and
9.35 mM Na2HPO4 (pH 7.4)). Samples plus 25 nM tritiated fMLP
(NEN Life Science Products, Inc., Boston, MA, USA) were added to
1U106 neutrophils in PBS and incubated on ice for 60 min. The cells
were then ¢ltered onto GF/B glass micro¢ber ¢lters (Whatman Inter-
national, Ltd., Maidstone, UK) and washed two times with PBS. The
¢lters were transferred to scintillation vials, and 3 ml Aquasol-2
(Packard Bioscience Co., Meriden, CT, USA) were added to each
vial. After shaking overnight, radioactivity was measured with a liquid
scintillation counter [11].
2.7. Superoxide anion generation assay
Superoxide anion (Oc32 ) production was measured by superoxide
dismutase inhibitable cytochrome c reduction [12]. Human neutrophils
were isolated by the same method as described in Section 2.6. Cyto-
chrome c solution (5 mM) and the isolated phagocytosis-stimulating
peptides were added to neutrophils (4U106 cells/ml) suspended in
HEPES-bu¡ered saline (150 mM NaCl, 5 mM HEPES, 1 mM CaCl2,
and 2 mM glucose) and incubated at 37‡C for 15 min with or without
superoxide dismutase (200 U/ml). The amount of Oc32 in the super-
natant was calculated using the following formula: nmol of Oc32 = 100/
21U(di¡erence in absorbance between 550 and 468 nm).
2.8. Determination of TNFK production
Peptides dissolved in 200 Wl saline were intraperitoneally or orally
administered to male ICR mice following 2 h of fasting (TNFK prim-
ing). 3 h later, 0.3 mg of the streptococcal preparation OK-432 (Chu-
gai Pharmaceutical Co. Ltd., Tokyo, Japan) suspended in 200 Wl
saline were intravenously injected (TNFK triggering). Blood was
collected 2 h later, and the TNFK concentration was measured with
a TNFK enzyme-linked immunosorbent assay (ELISA) kit (BioSource
International, Inc., Camarillo, CA, USA) [13].
3. Results
3.1. Puri¢cation and structure of the phagocytosis-stimulating
peptide
Phagocytosis-stimulating activity was detected in the £ow-
through fraction obtained from a DE52 column used to purify
a tryptic digest of soybean proteins. The £ow-through fraction
was separated on an ODS column (Fig. 1). The active fraction
was further puri¢ed with reversed-phase HPLC on Phenetyl
and ODS columns (Fig. 1). The active peptide is a tridecapep-
tide (Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn-Lys-Pro-Gly-Arg)
that corresponds to residues 173^185 of the soybean L-con-
glycinin KP subunit. The K and L subunits of soybean L-con-
glycinin also contain sequences similar to this tridecapeptide
except that the N-terminal Met is replaced by Leu and Ile,
respectively. Synthetic peptides corresponding to these se-
quences devoid of Met exhibited no activity (data not shown).
Fig. 1. Puri¢cation of a phagocytosis-stimulating peptide. The £ow-through fraction from a DEAE column was subjected to HPLC on an
ODS column and eluted on an acetonitrile gradient. Fractions that exhibited phagocytosis-stimulating activity were further puri¢ed on Phenetyl
and ODS columns (inset). Fractions containing soymetide-13 are indicated by arrows.
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This active peptide was named soymetide-13, since the Met at
its N-terminus is essential for its activity.
3.2. Structure^function relationship of the
phagocytosis-promoting soymetides
To con¢rm the minimum structure of soymetide-13 re-
quired for its immunostimulatory activity, we synthesized pep-
tides with amino acid residues deleted from either the N- or
C-termini. Phagocytosis-stimulating activity disappeared by
deletion of Met at the N-terminus. In contrast, activity grad-
ually increased as residues were removed from the C-terminus.
Although a statistical analysis was not performed, soymetide-
9 (Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn) exhibited the highest
immunostimulatory activity. Further deletion of residues from
the C-terminus resulted in decreased activity. Met-Ile-Thr dis-
played no activity, suggesting that Met-Ile-Thr-Leu (soyme-
tide-4) is the minimum sequence required for activity (Fig.
2A). The EC50 values (the concentration required for 50%
maximum activation) for phagocytotic activation of soyme-
tide-13, -9, and -4 were approximately 1, 0.5, and 30 WM,
respectively (Fig. 2B).
3.3. Identi¢cation of soymetides as fMLP agonists
We attempted to identify the receptor that mediates the
immunostimulatory activity of the various soymetides.
fMLP is a typical immunostimulating peptide that contains
a Met residue. A receptor binding assay with tritiated fMLP
and human neutrophils demonstrated that the soymetides can
bind to the fMLP receptor. The IC50 values of soymetide-4, -9
and -13 were 450, 25, and 50 WM, respectively (Table 1),
indicating that the soymetides are weak ligands for the
fMLP receptor.
Next, we tested the e¡ects of Boc-MLP, an fMLP antago-
nist [14], on the phagocytosis-stimulating activity of the soy-
metides. As shown in Fig. 2C, Boc-MLP completely inhibited
this activity. Together with the results described above, these
¢ndings reveal that immunomodulation of soymetides is medi-
ated by the fMLP receptor.
3.4. Stimulation of O2c3 release by soymetides
fMLP stimulates superoxide anion (Oc32 ) release from neu-
trophils at nanomolar levels [8]. We found that the soymetides
also weakly stimulated Oc32 release from human neutrophils.
At 10 WM, soymetides longer than soymetide-5 weakly stimu-
lated Oc32 generation, whereas soymetide-4 and -5 were inac-
tive (data not shown). Stimulation of Oc32 production by soy-
metide-13 was also blocked by Boc-MLP (data not shown).
3.5. Promotion of TNFK production
Following stimulation by fMLP, macrophages and neutro-
phils produce in£ammatory cytokines such as TNFK and in-
terleukin-1 (IL-1) [15]. TNFK production consists of two
steps: induction (priming) and release (triggering). Following
intraperitoneal administration in mice, soymetide-9 and fMLP
µ µ µ
µ
Fig. 2. A: Activation of phagocytosis by soymetides with C-terminal deletions. Human neutrophils were incubated with opsonized £uorescent
beads and 30 WM soymetides (n=3). Values are expressed as the meanRS.E.M. B: Concentration-dependent activation of phagocytosis by soy-
metide-4, -9, and -13 (n=2). C: E¡ect of the fMLP antagonist Boc-MLP (100 WM) on phagocytosis activated by soymetides (n=4). Values are
expressed as the meanRS.E.M.
Table 1
A⁄nities of soymetide-13 and its derivatives for fMLP receptor
Peptides IC50 (WM)
MITLAIPVNKPGR (soymetide-13) 50
MITLAIPVN (soymetide-9) 25
MITL (soymetide-4) 450
fMLF (fMLP) 0.03
Binding assay was performed in the presence of [3H]fMLP (25 nM)
using human neutrophils.
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exhibited statistically signi¢cant priming activity (Fig. 3A),
while soymetide-4 and -13 were inactive. In sharp contrast,
orally administered soymetide-4, which had the weakest
phagocytosis-stimulating activity in vitro (Fig. 2A), displayed
statistically signi¢cant priming of TNFK (Fig. 3B), unlike
soymetide-9, -13, and fMLP, which had no such e¡ect.
4. Discussion
Peptides produced in the mitochondrion and chloroplasts of
prokaryotes are usually formylated at their N-termini. N-for-
mylmethionyl peptides bind to the fMLP receptor on the sur-
face of macrophages and neutrophils in mammals and thereby
activate their immune systems. Immunostimulation following
binding of N-formylmethionyl peptides to the fMLP receptor
alerts the body that a bacterial infection is occurring.
Although soymetides derived from soybean protein are not
formylated at their N-termini, they exhibit weak a⁄nity for
the fMLP receptor. Therefore, following dietary ingestion of
soybeans, our immune systems receive a signal that is similar
to that received upon bacterial infection. Soymetide is the ¢rst
fMLP agonist peptide obtained from food protein.
fMLP induces three di¡erent responses in neutrophils de-
pending on its concentration [9]. It activates chemotaxis at a
peak concentration of 10310 M, elicits phagocytosis at 1039
M, and activates ROS production from 1038 M to a peak at
1036 M. At higher concentrations, fMLP stimulates both
phagocytosis and ROS production, which results in in£amma-
tion of the injured tissue. Soymetide-4 did not induce ROS
production in neutrophils in vitro, probably because its a⁄n-
ity for the fMLP receptor is much lower than that of fMLP.
Soymetide-4 could therefore theoretically be safely used as an
immunostimulatory agent without causing in£ammation.
Among the soymetides, soymetide-9 exhibited the highest
a⁄nity for the fMLP receptor as well as the strongest phago-
cytosis-stimulating activity in vitro. However, soymetide-4 in-
duces a stronger TNFK priming activity than soymetide-9,
-13, or fMLP following oral administration to mice. These
¢ndings could be explained if the larger peptides are not ab-
sorbed as well by the digestive system as the smaller peptides.
In support of this idea, the permeability of an N-formylme-
thionyl peptide through the intestinal mucosa was reported to
be very restricted [16]. The smaller soymetide-4 is therefore
more desirable than the other soymetides and fMLP for oral
administration. We found that soymetide-13 was converted to
soymetide-4 following incubation with pancreatic elastase in
vitro, suggesting that soymetide-4 may be released in the in-
testine following soybean ingestion.
In conclusion, soymetides with an a⁄nity for the fMLP
receptor are weak but safe immunostimulatory peptides. Soy-
metide-4 is the smallest but most e¡ective immunostimulatory
soymetide following oral administration. The various physio-
logical e¡ects that occur following oral administration of soy-
metide-4 are currently under investigation.
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